Introduction To The Clinical Pharmacy - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

Introduction To The Clinical Pharmacy

Description:

Introduction To The Clinical Pharmacy By Amgad A. Ragab, Pharm D, CCP New York University Medical College New York University Cancer Center New York USA – PowerPoint PPT presentation

Number of Views:550
Avg rating:3.0/5.0
Slides: 23
Provided by: uquEduSa
Category:

less

Transcript and Presenter's Notes

Title: Introduction To The Clinical Pharmacy


1
Introduction To The Clinical Pharmacy
  • By
  • Amgad A. Ragab, Pharm D, CCP
  • New York University Medical College
  • New York University Cancer Center
  • New York USA

2
Human Body
  • 44,701,295 VS 17.00
  • 1000 gm of Bone Marrow (23,ooo/gm) Total
    23,000,000
  • 7.5 gm of DNA (1.300,000/gm) Total 9.700,000
  • 109.2 gm of Immune globulin IgG (67,000/gm)
    Total 7,316,400
  • 210 units of erythropoietin hormone (5/u)
  • Total 1050.00

3
Human Body Organs
  • The Heart 57,000
  • The Liver 54,110
  • The Lung 58,200 X 2 116,400
  • The Kidney 45,700 X 2 194,000
  • The Pancrease 43,900
  • The Cornea 4,000 X 2 8,000
  • The Egg 7,000 each
  • The Sperm 75.00 each ejaculation

4
Human Chemistry
  • Iron 0.30 Potassium 5.95
  • Carbon 1.98 Calcium 0.18
  • Chloride 0.17 Phosphours 7.12
  • Iodide 0.01 Sulphur 1.60
  • Zinc 0.03 Sodium 0.11
  • TOTAL 17.00

5
CASE STUDY
  • A 52-year-old male was admitted to the hospital
    with fever and fatigue. Lab tests revealed that
    he was pancytopenic
  • WBC 1000, ANC 300, HGB 5.7, HCT 17 Platelets
    97,000, BUN 63, Creatinine 2.2
  • PMS Orthotopic heart transplant 14 months before
    this event
  • Medications Cyclosporine 100mg PO BID
    Azathioprine 150mg PO BID Prednisone
    10mg PO QD

6
CASE MANAGEMENT
  • Pt. was admitted to ICU with precautions related
    to neutropenia
  • He received a blood transfusion (4 units) for
    anemia
  • Broad-spectrum AB for neutropenia
  • Fluconazole and Ganciclovir for possible fungal
    or viral infections
  • BM biopsy for possible CMV infection

7
MEDICAL PROBLEM DISCOVERY
  • Clinical pharmacist interviewed the pt.
  • It was discovered that pt. was being treated with
    allopurinol 300mg PO QD for hyperuricemia
    (disorder associated with cyclosporin therapy) 2
    months before the hospitalization
  • Drug-drug interaction between allopurinol and
    azathioprine causes pancytopenia
  • Naranjo score is 7

8
(No Transcript)
9
MECHANISM OF ACTION
  • Azathioprine is metabolized to 6 mercaptopurine
    6-MP and then to inactive products by xanthine
    oxidase
  • Allopurinol is a xanthine oxidase inhibitor
  • Toxic effects on the bone marrow due to higher
    plasma concentration of 6-MP
  • Pt. remained in hospital for 31 days till the
    bone marrow slowly recovered
  • Total cost of this stay was 180,995,73

10
Intervention
  • It is recommended changes in the drug therapy for
    any of the following reasons
  • Untreated indication.
  • Drug use without an indication.
  • Improper drug selection.
  • Failure to receive drug
  • Subtherapeutic dosage
  • Overdose
  • Adverse Drug Reaction
  • Drug interaction
  • Inappropriate route
  • Monitoring required

11
ADVERSE DRUG EVENT (ADE)
  • Definition Any injury that results from the
    use of a drug

12
CLASSIFICATIONS OF ADE
  • Adverse Drug Reaction (ADR) Any response to
    a drug that is noxious and unintended and that
    occurs at doses normally used in humans for
    prophylaxis, diagnosis, or therapy of disease
  • Medication Error Any preventable drug event
    that may cause or lead to inappropriate
    medication use or patient harm
  • Therapeutic Failure
  • A suboptimal response to drug therapy

13
ADE CLASSIFICATIONS (CONT.)
  • Adverse Drug Withdrawal Event (ADWE)
  • A noxious or unintended response that
    occurs when a drug is discontinued (eg,
    benzodiazepines withdrawal, rebound hypertension
    with abrupt discontinuation of clonidine
  • Accidental/Intentional Overdose
  • A drug event due to a supratherapeutic level
    of a drug, either accidental (childhood
    poisoning) or intentional (suicide attempt)

14
(No Transcript)
15
INTERVENTION TO RESOLVE PATIENTS DRUG THERAPY
PROBLEM
  • The dose of azathioprine should be reduced by
    25-50
  • Azathioprine dosing should also be reduced in
    patients that have a renal insufficiency
  • Azathioprine ½ life elimination Parent drug
    12 minutes
  • 6-MP 0.7-3hrs
  • May be taken with food,3 hrs difference at least
    between azathioprine and allopurinol

16
CLASSIFICATION OF ADR
  • Type I Augmented reactions Related to
    pharmacologic effects eg hypoglycemic
    coma from insulin hypoprothrombinemia
    from warfarin 80-85 of all ADRs, considered
    predictable
  • Type II Bizarre reactions Related to
    hypersensitivity or immune mediated
    reactions 15-20 of all ADRs, considered
    unpredictable

17
ADEs HEALTH CARE SETTINGS
  • A Community
  • 18 of patients experience an ADE
  • More than 50 of office visits due to ADEs are
    preventable
  • 1.7-28 of ED visits are related to medication
    mismanagement (70 are preventable)
  • 5-10 of all hospitals admissions are related to
    ADEs
  • 1/3 of drug related hospitalizations involve
    patient noncompliance issues

18
CONT.
  • B. Hospitals
  • 10-30 of hospitalized patients experience an
    ADE, 1-3 significant
  • Each ADE costs approximately 5000
  • 30-50 of ADEs in hospitalized patients are
    preventable

19
CONT.
  • C. Long-term Care
  • 1.89 ADEs per 100 residents occur
  • More than 50 of ADEs are preventable
  • Polypharmacy The average number of medications
    taken by elderly patients 5-8 per day
  • The ADE rate among patients receiving 1-3 drugs
    6
  • More than 6 drugs the rate is 52

20
ADEs STATISTICS
  • Warfarin 95
  • Antidiabetic agents 94
  • NSAIDs 89
  • Digoxin 82
  • Antiepileptic drugs 69
  • Inadequate monitoring of drug therapy 67
  • Inappropriate dose 51
  • Patient compliance 33
  • Drug-drug interaction 26
  • Contraindication 3
  • Allergy 1

21
CONCLUSION
  • THE ANNUAL COST OF DRUG- RELATED MORBIDITY AND
    MORTALITY EXCEEDS 136 BILLION

22
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com